Description
Abirapro 250 mg contains Abiraterone Acetate, a selective androgen biosynthesis inhibitor. It is widely used in combination with prednisone or prednisolone for advanced prostate cancer management.
🔬 Mechanism of Action
Abiraterone inhibits the CYP17 (17α-hydroxylase/C17,20-lyase) enzyme, which is essential for androgen production in the testes, adrenal glands, and tumor tissues. As a result, it significantly reduces testosterone levels that fuel prostate cancer growth.
💊 Indications
Abirapro 250 mg is indicated for:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC)
It is administered in combination with corticosteroids to manage side effects related to mineralocorticoid excess.
📌 Key Features of Abirapro 250 m
- Strength: 250 mg
- Dosage Form: Oral tablet
- Therapeutic Class: Androgen Biosynthesis Inhibitor
- Administration: Typically 1000 mg once daily (4 tablets of 250 mg) taken on an empty stomach, along with prescribed prednisone
- Monitoring: Liver function tests, blood pressure, potassium levels, and fluid retention monitoring required
⚕️ Benefits of Abiraterone Acetate
- Effectively lowers testosterone levels
- Improves overall survival in advanced prostate cancer
- Oral administration for convenient dosing
- Standard therapy in modern prostate cancer treatment protocols
⚠️ Precautions
- Risk of liver toxicity
- May cause hypertension, hypokalemia, and fluid retention
- Regular monitoring of liver function and electrolytes necessary
- Avoid during pregnancy (not for use in women)
- Use strictly under oncologist supervision
Abirapro 250 mg (Abiraterone Acetate Tablets) is a key hormonal therapy for advanced prostate cancer, helping control disease progression and improve survival outcomes when used under specialized medical guidance.
